Delergotrile
| Clinical data | |
|---|---|
| Other names | CM 29-712; CM-29712; CM29-712; 6-Methylergoline-8α-acetonitrile; 6-Methyl-8α-(cyanomethyl)ergoline |
| Drug class | Dopamine receptor agonist; Antiparkinsonian agent |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C17H19N3 |
| Molar mass | 265.360 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Delergotrile (INN; developmental code name CM 29-712), also known as 6-methylergoline-8α-acetonitrile, is a dopamine receptor agonist of the ergoline family described as an antiparkinsonian agent which was never marketed. It is an analogue of lergotrile (LY-79907).
The drug shows high affinity for the dopamine D2 receptor (Ki = 34 nM). In addition to dopamine receptors, delergotrile shows affinity for the serotonin 5-HT1 receptor (K0.5 = 2.0 nM) and for the serotonin 5-HT2 receptor (Ki = 57 nM), as well as for the α1- and α2-adrenergic receptors. The drug appears to be an agonist of both dopamine D1 and to a lesser extent D2 receptors. Due to its dopamine receptor agonism, delergotrile produces antiparkinsonian-like effects, induces changes in locomotor activity and stereotypy, and reverses reserpine-induced akinesia in rodents. It also produces effects consistent with weak blockade of α-adrenergic receptors in rodents.
Delergotrile was first described in the literature by 1976. It was developed by Sandoz.
- Drugs not assigned an ATC code